CVA Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.9K | Buy |
61
+24
| +65% | +$7.83K | ﹤0.01% | 687 |
|
|
2025
Q1 | $9.99K | Buy |
37
+12
| +48% | +$3.24K | ﹤0.01% | 793 |
|
|
2024
Q4 | $5.88K | Buy |
25
+19
| +317% | +$4.47K | ﹤0.01% | 861 |
|
|
2024
Q3 | $1.65K | Buy |
+6
| New | +$1.65K | ﹤0.01% | 1004 |
|
|
2024
Q2 | – | Sell |
-3
| Closed | -$448 | – | 1277 |
|
|
2024
Q1 | $448 | Buy |
+3
| New | +$448 | ﹤0.01% | 1033 |
|
|
2023
Q3 | – | Sell |
-15
| Closed | -$2.85K | – | 255 |
|
|
2023
Q2 | $2.85K | Hold |
15
| – | – | ﹤0.01% | 860 |
|
|
2023
Q1 | $3.01K | Buy |
15
+5
| +50% | +$1K | ﹤0.01% | 828 |
|
|
2022
Q4 | $2.38K | Buy |
10
+5
| +100% | +$1.19K | ﹤0.01% | 815 |
|
|
2022
Q3 | $1K | Sell |
5
-5
| -50% | -$1K | ﹤0.01% | 832 |
|
|
2022
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 852 |
|
|
2022
Q1 | $2K | Buy |
+10
| New | +$2K | ﹤0.01% | 860 |
|